TEL AVIV, Israel, June 27, 2017 /PRNewswire/ -- Therapix
Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty
clinical-stage pharmaceutical company specializing in the
development of cannabinoid-based drugs, today announced that the
Company will ring The Nasdaq Stock Market Opening Bell in
New York, NY on Wednesday, June 28, 2017 in honor of its initial
public offering (IPO) of American Depository Shares (ADSs) listed
on the Nasdaq Capital Market in March
2017.
Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix,
stated, "We're proud to celebrate the successful uplisting to the
Nasdaq Capital Market as Therapix builds recognition in the U.S.
markets to grow exposure to a broader and more diverse investor
audience. As we ring the opening bell, I would also like to take
this moment to acknowledge and thank the employees, investors and
partners who have supported Therapix in our journey thus far. With
Therapix running two U.S. clinical studies in 2017 and data on one
of them to be released this year, today's celebration comes at a
landmark point in our timeline."
A live webcast of The Nasdaq Stock Market Opening Bell ceremony
will be available at https://livestream.com/nasdaq/live and also on
the Investor Relations portion of Therapix's website at
www.therapixbio.com.
Therapix began trading on the Nasdaq Capital Market on
March 22, 2017, under the symbol
"TRPX".
About Therapix Biosciences
Therapix Biosciences Ltd. (Nasdaq: TRPX) is a specialty
clinical-stage pharmaceutical company focused on developing
technologies and therapeutics based on cannabinoid pharmaceuticals.
The Company's clinical pipeline assets follow a de-risked 505(b)(2)
regulatory pathway benefitting from Therapix's unique proprietary
formulations based on repurposing an FDA approved synthetic
cannabinoid (dronabinol). Therapix's lead compound, THX-TS01, is
currently in Phase 2 clinical trials for Tourette's Syndrome and
the Company intends to initiate a Phase 1 clinical study of
THX-ULD01 for the treatment of Mild Cognitive Impairment, for which
no FDA-approved therapies currently exist. Please visit our website
for more information at www.therapixbio.com.
Contacts
Josh Blacher
Chief Financial Officer
josh@therapixbio.com
Tirth Patel (investors)
Edison Group
tpatel@edisongroup.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/therapix-biosciences-to-ring-the-nasdaq-stock-market-opening-bell-on-june-28-300480633.html
SOURCE Therapix Biosciences Ltd